GO
| HSI1 | 26,009.46 | 0.00 | -- |
| HSCEI1 | 8,634.34 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
SBP GROUP (01177.HK)'s Innovative ActRII A/B Monoclonal Antibody Approved for Clinical Study
2026-08-23 18:05:43 SBP GROUP (01177.HK) announced that TQF6422 injection, an "ActRII A/B monoclonal antibody" independently developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group as a Class 1 innovative drug in China, has been approved by the Center for Drug Evaluation of the National Medical Products Administration of China to commence clinical studies. The drug is intended for weight management in adult obesity patients, or overweight patients with at least one weight-related comorbidity. Preclinical study results of TQF6422 showed that its in vitro activity was more than 10 times higher than comparable products. In multiple animal efficacy models, it achieved superior fat reduction and lean mass preservation at lower doses. In combination with GLP-1, it demonstrated synergistic effects with dual benefits in fat reduction and muscle gain. It also showed favorable pharmacokinetic and safety profiles. (de/d)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |